Disease · MONDO_0006502
Comparisons in its trials92
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 92
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Early Neuromuscular Blockade (NMB) vs Control: No Routine Early NMB: deaths from any cause | 213 of 501 | 216 of 505 | 1,006 | NCT02509078 | Trial comparisons |
| Early Neuromuscular Blockade (NMB) vs Control: No Routine Early NMB: serious adverse events | 28 of 501 | 21 of 505 | 1,006 | NCT02509078 | Trial comparisons |
| Rosuvastatin vs Placebo: serious adverse events | 34 of 379 | 32 of 366 | 745 | NCT00979121 | Trial comparisons |
| Vadadustat vs Placebo: deaths from any cause | 19 of 221 | 19 of 227 | 448 | NCT04478071 | Trial comparisons |
| Vadadustat vs Placebo: serious adverse events | 61 of 221 | 73 of 227 | 448 | NCT04478071 | Trial comparisons |
Vadadustat vs Placebo: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High Flow Oxygen Devices) on the NIAID Ordinal Scale | 43 of 216 | 53 of 223 | 439 | NCT04478071 | Trial comparisons |
| Vadadustat vs Placebo: Number of Participants With a Total Score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) Scale | 156 of 214 | 157 of 223 | 437 | NCT04478071 | Trial comparisons |
| Brensocatib vs Placebo: Cumulative Incidence of Serious Adverse Events (SAEs) | 40 of 192 | 35 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: Discontinuation or Temporary Suspension of Treatment | 13 of 192 | 12 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: deaths from any cause | 29 of 192 | 23 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: serious adverse events | 40 of 192 | 35 of 214 | 406 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: Improvement of One Category From Admission Using 7-point Ordinal Scale. | 159 of 190 | 186 of 214 | 404 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: Number of Participants Discharged or to a National Early Warning Score (NEWS) of Equal or Less Than 2 and Maintained for 24 Hours, Whichever Occurs First. | 172 of 190 | 195 of 214 | 404 | NCT04817332 | Trial comparisons |
| Brensocatib vs Placebo: 28-day Mortality | 29 of 190 | 23 of 214 | 404 | NCT04817332 | Trial comparisons |
| FP-1201-lyo 10 μg vs Placebo: Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360 | 51 of 144 | 53 of 152 | 296 | NCT02622724 | Trial comparisons |
| FP-1201-lyo 10 μg vs Placebo: Efficacy Endpoint: Mortality in Hospital | 1 of 144 | 0 of 152 | 296 | NCT02622724 | Trial comparisons |
| FP-1201-lyo 10 μg vs Placebo: deaths from any cause | 51 of 144 | 53 of 152 | 296 | NCT02622724 | Trial comparisons |
| FP-1201-lyo 10 μg vs Placebo: serious adverse events | 77 of 144 | 77 of 152 | 296 | NCT02622724 | Trial comparisons |
| Albuterol Sulfate vs Placebo: serious adverse events | 1 of 152 | 1 of 130 | 282 | NCT00434993 | Trial comparisons |
| Early Neuromuscular Blockade (NMB) vs Control: No Routine Early NMB: PTSS-14: Post-traumatic Stress-like Symptoms Scores >/= 45 | 38 of 145 | 31 of 122 | 267 | NCT02509078 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006502/comparisons